Lexeo to start phase I/II clinical trial for patients with FA cardiomyopathy

May 26, 2022

Gene therapy company Lexeo Therapeutics in 2022 plans to launch a phase I/II clinical trial of its adeno-associated virus-based therapy designed to intravenously deliver a functional frataxin gene for the treatment of Friedreich’s ataxia (FA) cardiomyopathy.

CEO Nolan Townsend told ScienceBoard.net at the American Society of Gene & Cell Therapy (ASGCT) 2022 annual meeting in Washington, DC that LX2006, whose investigational new drug application was recently cleared by the U.S. Food and Drug Administration, is the first disease-modifying, clinical-stage gene therapy treatment for Friedreich's ataxia and the first clinical-stage program from the company's cardiovascular gene therapy pipeline.

FA, a rare, progressive neurogenetic condition found in approximately 1 in 50,000 people, is characterized by progressive lack of coordinated movement and loss of balance. FA patients may also experience cardiac dysfunction, scoliosis, diabetes, and vision and hearing difficulties.

"This is typically known as a neurologic disease for patients that begins in childhood," Townsend said. "This typically progresses until they reach adulthood when a form of cardiomyopathy associated with the disease emerges. And it's this cardiac disease that's actually the cause of death for up to 70% of Friedreich's ataxia patients."

At ASGCT 2022, Lexeo presented new preclinical data supporting its FA cardiomyopathy program, as well as separate presentations on the company's plakophilin-2 arrhythmogenic right ventricular cardiomyopathy and second-generation APOE4 Alzheimer's disease programs.

Watch the video below to learn more.


COVID-19 mRNA-based vaccines benefit from decades of research
25 years ago Dr. Drew Weissman, PhD, an infectious disease expert at Penn Medicine, and RNA biologist Kati Kariko, PhD, began their collaboration in...
Genenta Science reports preliminary results of Temferon-glioblastoma study
Biotech company Genenta Science is developing a proprietary hematopoietic stem cell gene therapy, Temferon, for the treatment of a variety of solid tumor...
Next-generation AAV capsids hold key to developing life-changing therapies
Voyager Therapeutics’ discovery platform is identifying novel capsids targeting desired cells and tissues with greater specificity, at lower doses, and...
How to address challenges in producing AAV vectors
There are challenges in producing sufficient quantities of gene therapy products, particularly when it comes to adeno-associated virus (AAV) vectors,...
Atsena Therapeutics’ gene therapy takes aim at childhood blindness
In an interview with ScienceBoard.net, Patrick Ritschel, CEO of Ophthalmology-based gene therapy company Atsena Therapeutics, shared an overview...
Omega Therapeutics looks to tap 'nature's operating system' to control gene expression
Precision genomic medicine company Omega Therapeutics is looking to harness “nature’s operating system” for controlling gene expression and cell differentiation,...
Delivery of gene therapies remains a key challenge
Gene therapy holds great promise for treating inherited disorders, cancers, and other diseases, but delivery of these therapies remains a key challenge,...
Next evolution of CAR T-cell therapy is solid tumors
While chimeric antigen receptor (CAR) T-cell therapy has become a game changer for some patients with blood cancer, the next area of evolution for the...

Copyright © 2022 scienceboard.net

Last Updated 5/27/2022 11:44:01 AM